LibbyPBuringJEBadimonL, et al.Atherosclerosis. Nat Rev Dis Primers2019; 5: 56.
2.
RochaVZSantosRD. Cholesterol and inflammation: the lesser the better in atherothrombosis. Eur J Prev Cardiol2018; 25: 944–947.
3.
KaptogeSSeshasaiSRGaoP, et al.Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J2014; 35: 578–589.
4.
RidkerPM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circulation Res2016; 118: 145–156.
5.
SarwarNButterworthASet al.IL-6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet2012; 379: 1205–1213.
6.
Interleukin-6 Receptor Mendelian Randomisation Analysis ConsortiumSwerdlowDIHolmesMV, et al.The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet2012; 379: 1214–1224.
7.
RidkerPMEverettBMThurenT, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–1131.
8.
RidkerPMLibbyPMacFadyenJG, et al.Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J2018; 39: 3499–3507.
9.
ZieglerLGajulapuriAFrumentoP, et al.Interleukin 6 trans-signalling and risk of future cardiovascular events. Cardiovasc Res2019; 115: 213–221.
10.
RidkerPMDanielsonEFonsecaFA, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359: 2195–2207.
11.
LibbyPRochaVZ. All roads lead to IL-6: a central hub of cardiometabolic signaling. Int J Cardiol2018; 259: 213–215.
12.
AlbaACAgoritsasTWalshM, et al.Discrimination and calibration of clinical prediction models: users' guides to the medical literature. JAMA2017; 318: 1377–1384.
13.
PradhanADAdayAWRoseLM, et al.Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation2018; 138: 141–149.
14.
BohulaEAGiuglianoRPLeiterLA, et al.Inflammatory and cholesterol risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk). Circulation2018; 138: 131–140.
15.
ZieglerLFFrumentoPWallénH, et al.The predictive role of IL6 trans-signalling in middle-aged men and women at low–intermediate risk of cardiovascular events. Eur J Prev Cardiol. 2020; 27: 122–129.
16.
BuckleyDIFuRFreemanM, et al.C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med2009; 151: 483–495.
17.
YeboahJMcClellandRLPolonskyTS, et al.Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA2012; 308: 788–795.
18.
SchuettHOestreichRWaetzigGH, et al.Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol2012; 32: 281–290.
